Assessment of left ventricular diastolic function with pioglita zone in type 2 diabetic patients;Japanese Source

Journal of Cardiology

Volumn 48, Issue 5, 2006, Pages 263-267

  Terui, Gen ^a   Goto, Takashi ^a   Katsuta, Mitsuaki ^a   Aoki, Isamu ^a  

^a AKITA RED CROSS HOSPITAL   (Japan)

Author keywords

Diabetes mellitus; Diastole; Echocardiography; Transthoracic; Ventricular function

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PIOGLITAZONE;

AGED; ARTICLE; DIASTOLE; ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HUMAN; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

AGED; DIABETES MELLITUS, TYPE 2; DIASTOLE; ECHOCARDIOGRAPHY; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; THIAZOLIDINEDIONES; VENTRICULAR FUNCTION, LEFT;

EID: 39049174100     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K: Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670-1675
2. Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS: Left-ventricular dias-tolic dysfunction may be prevented by chronic treatment with PPAR- α or- γ agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 2003; 19: 487-493
3. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005; 111: 583-590
4. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977; 55: 613-618
5. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, Seward JB: New index of combined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function: A study in normals and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366
6. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118
7. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD : Thiazolidinediones expand body fluid volume through PPAR / stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866
8. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Winter ML, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association: Thiazolidinediones use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108: 2941-2948
9. Delerive P, Fruchart JC, Staels B: Peroxisome prolifera-tors-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459
10. Tsuji T, Mizushige K, Noma T, Murakami K, Ohmori K, Miyatake A, Kohno M: Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rats, J Cardiovasc Pharmacol 2001; 38: 868-874
11. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: Results from a controlled randomized study. Circulation 2005; 111: 2525-2531
12. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control : Results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931
13. Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S: Glitazones and heart failure: Critical appraisal for clinician. Circulation 2003; 107: 1350-1354
14. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351
15. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, on behalf of the PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactives Study (PRO spective pioglitAzone Clinical Trial In macroVascuIar Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289
16. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A: Pioglitazone, a peroxisome proliferators-activated receptor- γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation2002; 106: 3126-3132
17. Zhu P, Lu L, Xu Y, Schwartz GG: Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000; 101: 1165-1171
18. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y: Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005; 18: 949-957